Approved by the Food and Drug Administration (FDA) in 2002, Buprenorphine is being used in opioid addiction treatment in the forms of Subutex and Suboxone.  Buprenorphine is trademarked as the only pharmacological treatment for opioid dependence available in office-based settings and has the potential to increase access to the estimated 3.5 million untreated prescription opioid and heroin dependent individuals.  Despite the large potential, the rate of usage by prescribing physicians is lagging.

A Project of the Governor's Institute on Alcohol & Substance Abuse and the North Carolina Society of Addiction Medicine.
Funded wholly or in part by the federal Substance Abuse Prevention and Treatment Block Grant Fund (CFDA #93.959) as a project of the NC Division of Mental Health, Developmental Disabilities & Substance Abuse Services.